UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Mycoplasma pneumoniae infection in children

Authors
Dori F Zaleznik, MD
Jesus G Vallejo, MD
Section Editor
Morven S Edwards, MD
Deputy Editor
Mary M Torchia, MD

INTRODUCTION

Mycoplasma pneumoniae is one of three species of Mycoplasma that frequently produce infection in humans. Mycoplasmas are ubiquitous and are the smallest bacteria that can survive alone in nature. M. pneumoniae causes a wide variety of clinical manifestations in children and adults, principally pneumonia.

The clinical features, diagnosis, and treatment of M. pneumoniae infection in children will be reviewed here. M. pneumoniae infection in adults, M. hominis, M genitalium, and Ureaplasma urealyticum infections are discussed separately. (See "Mycoplasma pneumoniae infection in adults" and "Mycoplasma hominis and Ureaplasma urealyticum infections".)

MICROBIOLOGY

The term "mycoplasma" is widely used to refer to any organism within the class Mollicutes, which is composed of five genera (Mycoplasma, Ureaplasma, Acholeplasma, Anaeroplasma, and Asteroloplasma). More than 120 named Mycoplasma species exist, and 13 Mycoplasma species, two Acholeplasma species, and one Ureaplasma species have been isolated from humans. However, only four species are well-established human pathogens [1]:

Mycoplasma pneumoniae

Mycoplasma hominis

                            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri May 13 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Taylor-Robinson D. Infections due to species of Mycoplasma and Ureaplasma: an update. Clin Infect Dis 1996; 23:671.
  2. Gillespie SH, Ling CL, Oravcova K, et al. Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen. Clin Infect Dis 2015; 60:381.
  3. Pereyre S, Renaudin H, Touati A, et al. Detection and susceptibility testing of Mycoplasma amphoriforme isolates from patients with respiratory tract infections. Clin Microbiol Infect 2010; 16:1007.
  4. Ling CL, Oravcova K, Beattie TF, et al. Tools for detection of Mycoplasma amphoriforme: a primary respiratory pathogen? J Clin Microbiol 2014; 52:1177.
  5. Baseman JB, Tully JG. Mycoplasmas: sophisticated, reemerging, and burdened by their notoriety. Emerg Infect Dis 1997; 3:21.
  6. Feizi T, Loveless RW. Carbohydrate recognition by Mycoplasma pneumoniae and pathologic consequences. Am J Respir Crit Care Med 1996; 154:S133.
  7. Baseman JB, Reddy SP, Dallo SF. Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections. Am J Respir Crit Care Med 1996; 154:S137.
  8. Martin RE, Bates JH. Atypical pneumonia. Infect Dis Clin North Am 1991; 5:585.
  9. Luby JP. Pneumonia caused by Mycoplasma pneumoniae infection. Clin Chest Med 1991; 12:237.
  10. Clyde WA Jr. Clinical overview of typical Mycoplasma pneumoniae infections. Clin Infect Dis 1993; 17 Suppl 1:S32.
  11. Mogabgab WJ. Mycoplasma pneumoniae and adenovirus respiratory illnesses in military and university personnel, 1959-1966. Am Rev Respir Dis 1968; 97:345.
  12. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372:835.
  13. Foy HM, Kenny GE, Cooney MK, Allan ID. Long-term epidemiology of infections with Mycoplasma pneumoniae. J Infect Dis 1979; 139:681.
  14. Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 2013; 10:e1001444.
  15. Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis 2001; 1:334.
  16. Wang K, Gill P, Perera R, et al. Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia. Cochrane Database Syst Rev 2012; 10:CD009175.
  17. Mansel JK, Rosenow EC 3rd, Smith TF, Martin JW Jr. Mycoplasma pneumoniae pneumonia. Chest 1989; 95:639.
  18. Kotikoski MJ, Kleemola M, Palmu AA. No evidence of Mycoplasma pneumoniae in acute myringitis. Pediatr Infect Dis J 2004; 23:465.
  19. Martin RJ, Chu HW, Honour JM, Harbeck RJ. Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. Am J Respir Cell Mol Biol 2001; 24:577.
  20. Biscardi S, Lorrot M, Marc E, et al. Mycoplasma pneumoniae and asthma in children. Clin Infect Dis 2004; 38:1341.
  21. Atkinson TP, Duffy LB, Pendley D, et al. Deficient immune response to Mycoplasma pneumoniae in childhood asthma. Allergy Asthma Proc 2009; 30:158.
  22. Olson D, Watkins LK, Demirjian A, et al. Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome. Pediatrics 2015; 136:e386.
  23. Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol 2015; 72:239.
  24. Vujic I, Shroff A, Grzelka M, et al. Mycoplasma pneumoniae-associated mucositis--case report and systematic review of literature. J Eur Acad Dermatol Venereol 2015; 29:595.
  25. Meyer Sauteur PM, Goetschel P, Lautenschlager S. Mycoplasma pneumoniae and mucositis--part of the Stevens-Johnson syndrome spectrum. J Dtsch Dermatol Ges 2012; 10:740.
  26. Cherry JD. Anemia and mucocutaneous lesions due to Mycoplasma pneumoniae infections. Clin Infect Dis 1993; 17 Suppl 1:S47.
  27. Pemira SM, Tolan RW Jr. Mycoplasma pneumoniae infection presenting as bullous papular purpuric gloves and socks syndrome: novel association and review of the literature. Clin Pediatr (Phila) 2011; 50:1140.
  28. Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review. Clin Infect Dis 1993; 17 Suppl 1:S52.
  29. Smith R, Eviatar L. Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature. Clin Pediatr (Phila) 2000; 39:195.
  30. Candler PM, Dale RC. Three cases of central nervous system complications associated with Mycoplasma pneumoniae. Pediatr Neurol 2004; 31:133.
  31. Christie LJ, Honarmand S, Talkington DF, et al. Pediatric encephalitis: what is the role of Mycoplasma pneumoniae? Pediatrics 2007; 120:305.
  32. Walter ND, Grant GB, Bandy U, et al. Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness. J Infect Dis 2008; 198:1365.
  33. Weng WC, Peng SS, Wang SB, et al. Mycoplasma pneumoniae--associated transverse myelitis and rhabdomyolysis. Pediatr Neurol 2009; 40:128.
  34. Lin JJ, Hsia SH, Wu CT, et al. Mycoplasma pneumoniae-related postencephalitic epilepsy in children. Epilepsia 2011; 52:1979.
  35. Al-Zaidy SA, MacGregor D, Mahant S, et al. Neurological Complications of PCR-Proven M. pneumoniae Infections in Children: Prodromal Illness Duration May Reflect Pathogenetic Mechanism. Clin Infect Dis 2015; 61:1092.
  36. Kenny GE, Kaiser GG, Cooney MK, Foy HM. Diagnosis of Mycoplasma pneumoniae pneumonia: sensitivities and specificities of serology with lipid antigen and isolation of the organism on soy peptone medium for identification of infections. J Clin Microbiol 1990; 28:2087.
  37. Reittner P, Müller NL, Heyneman L, et al. Mycoplasma pneumoniae pneumonia: radiographic and high-resolution CT features in 28 patients. AJR Am J Roentgenol 2000; 174:37.
  38. Niitu Y. M. pneumoniae respiratory diseases: clinical features--children. Yale J Biol Med 1983; 56:493.
  39. Kim CK, Chung CY, Kim JS, et al. Late abnormal findings on high-resolution computed tomography after Mycoplasma pneumonia. Pediatrics 2000; 105:372.
  40. Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol 1996; 35:757.
  41. Nagayama Y, Sakurai N, Yamamoto K. Clinical observations of children with pleuropneumonia due to Mycoplasma pneumoniae. Pediatr Pulmonol 1990; 8:182.
  42. Thurman KA, Walter ND, Schwartz SB, et al. Comparison of laboratory diagnostic procedures for detection of Mycoplasma pneumoniae in community outbreaks. Clin Infect Dis 2009; 48:1244.
  43. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.
  44. Touati A, Benard A, Hassen AB, et al. Evaluation of five commercial real-time PCR assays for detection of Mycoplasma pneumoniae in respiratory tract specimens. J Clin Microbiol 2009; 47:2269.
  45. Loens K, Goossens H, Ieven M. Acute respiratory infection due to Mycoplasma pneumoniae: current status of diagnostic methods. Eur J Clin Microbiol Infect Dis 2010; 29:1055.
  46. Baron EJ, Miller JM, Weinstein MP, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin Infect Dis 2013; 57:e22.
  47. Tjhie JH, van Kuppeveld FJ, Roosendaal R, et al. Direct PCR enables detection of Mycoplasma pneumoniae in patients with respiratory tract infections. J Clin Microbiol 1994; 32:11.
  48. Blackmore TK, Reznikov M, Gordon DL. Clinical utility of the polymerase chain reaction to diagnose Mycoplasma pneumoniae infection. Pathology 1995; 27:177.
  49. Ramirez JA, Ahkee S, Tolentino A, et al. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagn Microbiol Infect Dis 1996; 24:7.
  50. Xu D, Li S, Chen Z, Du L. Detection of Mycoplasma pneumoniae in different respiratory specimens. Eur J Pediatr 2011; 170:851.
  51. American Academy of Pediatrics. Mycoplasma pneumoniae and other Mycoplasma species infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW, Brady MT, Jackson MA, Long SS. (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.568.
  52. US Food and Drug Administration (FDA) News Release. FDA expands use for FilmArray Respiratory Panel. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm304177.htm (Accessed on June 11, 2012).
  53. Poritz MA, Blaschke AJ, Byington CL, et al. FilmArray, an automated nested multiplex PCR system for multi-pathogen detection: development and application to respiratory tract infection. PLoS One 2011; 6:e26047.
  54. Idaho Technology Inc. FilmArray Respiratory Panel - Information Sheet. http://www.idahotech.com/pdfs/FilmArray/InfoSheet,%20FilmArray%20Respiratory%20Panel-0229.pdf (Accessed on June 11, 2012).
  55. Baum SG. Mycoplasma pneumoniae and atypical pneumonia. In: Principles and Practice of Infectious Diseases, 7th Ed, Mandell GL, Bennett JE, Dolin R. (Eds), Churchill Livingstone, Philadelphia 2010. p.2481.
  56. Jacobs E. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures. Clin Infect Dis 1993; 17 Suppl 1:S79.
  57. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004; 17:697.
  58. Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect 2003; 9:263.
  59. Nir-Paz R, Michael-Gayego A, Ron M, Block C. Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection. Clin Microbiol Infect 2006; 12:685.
  60. Thacker WL, Talkington DF. Comparison of two rapid commercial tests with complement fixation for serologic diagnosis of Mycoplasma pneumoniae infections. J Clin Microbiol 1995; 33:1212.
  61. Beersma MF, Dirven K, van Dam AP, et al. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol 2005; 43:2277.
  62. Talkington DF, Shott S, Fallon MT, et al. Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol 2004; 11:862.
  63. Busson L, Van den Wijngaert S, Dahma H, et al. Evaluation of 10 serological assays for diagnosing Mycoplasma pneumoniae infection. Diagn Microbiol Infect Dis 2013; 76:133.
  64. Marmion BP, Williamson J, Worswick DA, et al. Experience with newer techniques for the laboratory detection of Mycoplasma pneumoniae infection: Adelaide, 1978-1992. Clin Infect Dis 1993; 17 Suppl 1:S90.
  65. Biondi E, McCulloh R, Alverson B, et al. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics 2014; 133:1081.
  66. Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14:471.
  67. Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev 2015; 1:CD004875.
  68. Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 2011; 6:423.
  69. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8:214.
  70. KINGSTON JR, CHANOCK RM, MUFSON MA, et al. Eaton agent pneumonia. JAMA 1961; 176:118.
  71. Colin AA, Yousef S, Forno E, Korppi M. Treatment of Mycoplasma pneumoniae in pediatric lower respiratory infection. Pediatrics 2014; 133:1124.
  72. Hersh AL, Shapiro DJ, Pavia AT, Shah SS. Antibiotic prescribing in ambulatory pediatrics in the United States. Pediatrics 2011; 128:1053.
  73. Peuchant O, Ménard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64:52.
  74. Averbuch D, Hidalgo-Grass C, Moses AE, et al. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis 2011; 17:1079.
  75. Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J 2012; 31:409.
  76. Kawai Y, Miyashita N, Yamaguchi T, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 2012; 17:354.
  77. Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother 2011; 66:734.
  78. Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012; 55:1642.
  79. Kawai Y, Miyashita N, Kubo M, et al. Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother 2013; 57:4046.
  80. Zheng X, Lee S, Selvarangan R, et al. Macrolide-Resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis 2015; 21:1470.
  81. Diaz MH, Benitez AJ, Cross KE, et al. Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States. Open Forum Infect Dis 2015; 2:ofv106.
  82. Yoo SJ, Kim HB, Choi SH, et al. Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance. Antimicrob Agents Chemother 2012; 56:6393.
  83. Bradley JS, Jackson MA, Committee on Infectious Diseases, American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics 2011; 128:e1034.
  84. US Food and Drug Administration. FDA Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 13, 2016).
  85. Chien S, Wells TG, Blumer JL, et al. Levofloxacin pharmacokinetics in children. J Clin Pharmacol 2005; 45:153.
  86. American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th, Kimberlin DW, Brady MT, Jackson MA, Long SS. (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.881.
  87. Yiş U, Kurul SH, Cakmakçi H, Dirik E. Mycoplasma pneumoniae: nervous system complications in childhood and review of the literature. Eur J Pediatr 2008; 167:973.
  88. Daxboeck F. Mycoplasma pneumoniae central nervous system infections. Curr Opin Neurol 2006; 19:374.